Patent · US Active

Inflammasome activation in myelodysplastic syndromes

US10688077B2 · kind B2 · utility

0Cited by

2References

11Claims

0Family size

Assignee

H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC. · US

Inventors

Sheng Wei · Tampa, US
Alan F. List · Tampa, US

Key dates

Filing date	Feb 26, 2016
Grant date	Jun 23, 2020
Priority date	—
Expiry date	Feb 26, 2036

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/7095
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are methods for treating a meylodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of an inflammasome inhibitor. Also disclosed are methods for diagnosing a myelodysplastic syndrome (MDS) in a subject. In some embodiments, the method involves assaying a sample from the subject to detect inflammasome activation, wherein an increase in inflammasome activation in the sample compared to a control is an indication of MDS in the subject. In some embodiments, the method involves assaying a sample from the subject to detect s100A9 protein levels, wherein an increase in s100A9 protein levels in the sample compared to a control is an indication of MDS in the subject. The disclosed methods can further involve treating the subject for MDS if an increase in inflammasome activation and/or s100A9 levels are detected.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.